The idiopathic hypereosinophilic syndrome: Clinical presentation, pathogenesis and therapeutic strategies

Drugs of Today

Volumn 34, Issue 4, 1998, Pages 361-373

  Roufosse, F ^a   Bartholome E ^a   Schandene L ^a   Goldman, M ^a   Cogan, E ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 5; VINCRISTINE;

ANEMIA; BLOOD TOXICITY; BRAIN DISEASE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MECHANISM; FLU LIKE SYNDROME; HELPER CELL; HUMAN; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; PROGNOSIS; REVIEW; THROMBOCYTOPENIA;

EID: 0031956017     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1998.34.4.485234     Document Type: Review

References (75)

1. Hardy, W.R., Anderson, R.E. The hypereosinophilic syndromes. Ann Intern Med 1968, 68: 1220-9.
2. Chusid, M.J., Dale, D.C., West, B.C., Wolff, S.M. The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine 1975, 54: 1-27.
3. Fauci, A.S., Harley, J.B., Roberts, W.C., Ferrans, V.J., Gralnick, H.R., Bjornson, B.H. NIH Conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982, 97: 78-92.
4. Weller, P.F., Bubley, G.J. The idiopathic hypereosinophilic syndrome. Blood 1994, 83: 2759-79.
5. Parillo, J.E., Fauci, A.S., Wolff, S.M. Therapy of the hypereosinophilic syndrome. Ann Intern Med 1978, 89: 167-72.
6. Wardlaw, A.J. Eosinophils in the 1990s: New perspectives on their role in health and disease. Postgrad Med J 1994, 70: 536-52.
7. Weller, P.F. The immunobiology of eosinophils. New Engl J Med 1991, 324: 1110-8.
8. Gleich, G.J., Adolphson, C.R., Leiferman, K.M. The biology of the eosinophilic leukocyte. Annu Rev Med 1993, 44: 85-101.
9. Sanderson, C.J. Interleukin-5, eosinophils and diseases. Blood 1992, 79: 3101-9.
10. Simon, H-U., Blaser, K. Inhibition of programmed eosinophil death: A key pathogenic event for eosinophilia? Immunol Today 1995, 16: 53-5.
11. Her, E., Frazer, J., Austen, K.F., Owen, W.F. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin Invest 1991, 88: 1982-7.
12. Desreumaux, P., Capron, M. Eosinophils in allergic reactions. Curr Opin Immunol 1996, 8: 790-5.
13. Rand, T.H., Silberstein, D.S., Kornfeld, H., Weller, P.F. Human eosinophils express functional interleukin 2 receptors. J Clin Invest 1991, 88: 825-32.
14. Enokihara, H., Furusawa, S., Nakakubo, H. et al. T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. Blood 1989, 73: 1809-13.
15. Ponath, P.D., Qin, S., Post, T.W. et al. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med 1996, 183: 2437-48.
16. Elsner, J., Höchstetter, R., Kimmig, D., Kapp, A. Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol 1996, 26: 1919-25.
17. Prin, L., Capron, M., Tonnel, A.B., Bletry, O., Capron, A. Heterogeneity of human peripheral blood eosinophils: Variability in cell density and cytotoxic ability in relation to the level and the origin of hypereosinophilia. Int Arch Allergy Appl Immunol 1983, 72: 336-46.
18. Owen, W.F., Rothenberg, M.E., Petersen, J. et al. Interleukin-5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 1989, 170: 343-8.
19. Prin, L., Plumas, J., Gruart, V. et al. Elevated serum levels of soluble interleukin-2 receptor: A marker of disease activity in the hypereosinophilic syndrome. Blood 1991, 78: 2626-32.
20. Gonzalo, J.A., Lloyd, C.M., Kremer, L. et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. J Clin Invest 1996, 98: 2332-45.
21. Walsh, G.M. Human eosinophils: Their accumulation, activation and fate. Br J Haematol 1997, 97: 701-9.
22. Garcia-Zepeda, E.A., Rothenberg, M.E., Ownbey, R.T., Celestin, J., Leder, P., Luster, A.D. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996, 2: 449-56.
23. Heath, H., Qin, S., Rao, P. et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997, 99: 178-84.
24. Mould, A.W., Matthaei, K.I., Young, I.G., Foster, P.S. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 1997, 99: 1064-71.
25. Mosmann, T.R., Coffman, R.L. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989, 7: 145-73.
26. Romagnani, S. Short analytical review. TH1 and TH2 in human diseases. Clin Immunol Immunopathol 1996, 80: 225-35.
27. Cogan, E., Schandené, L., Crusiaux, A., Cochaux, P., Velu, T., Goldman, M. Brief report: Clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. New Engl J Med 1994, 330: 535-8.
28. Roufosse, F., Schandené, L., Kennes, B. et al. Involvement of CDS-negative TH2 clones in the pathogenesis of the idiopathic hypereosinophilic syndrome. IVth Int Symp Clin Immunol (June 19-22, Amsterdam) 1997, Abst 2. P.10.
29. + T-cell population able to secrete large amounts of interleukin-5. Blood 1996, 87: 1416-22.
30. Simon, H.U., Yousefi, S., Dommann-Scherrer, C.C. et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996, 183: 1071-82.
31. O'Shea, J.J., Jaffe, E.S., Lane, H.C., MacDermott, R.P., Fauci, A.S. Peripheral T cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features. Am J Med 1987, 82: 539-46.
32. Bagot, M., Bodemer, C., Wechsler, J. Lymphome T non épidermotrope précédé pendant plusieurs années par un syndrome hyperéosinophilique. Ann Dermatol Venereol 1990, 117: 883-5.
33. Schleimer, R.P., Bochner, B.S. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 1994, 94: 1202-13.
34. Wallen, N., Kita, H., Weiler, D., Gleich, G.J. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991, 147: 3490-5.
35. Kwon, O.J., Jose, P.J., Robbins, R.A., Schall, T.J., Williams, T.J., Barnes, B.J. Glucocorticoid inhibition of RANTES expression in human lung epithelial cells. Am J Respir Cell Mol Biol 1995, 12: 488-96.
36. Lilly, C.M., Nakamura, H., Kesselman, H. et al. Expression of eotaxin by human lung epithelial cells. Induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997, 99: 1767-73.
37. Prin, L., Lefebvre, P., Gruart, V. et al. Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: Absence of detectable receptor correlates with resistance to corticotherapy. Clin Exp Immunol 1989, 78: 383-9.
38. Malbrain, M.L., Van den Bergh, H., Zachée, P. Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: Complete haematological and cytogenetic remission induced by interferon-α in a case with a unique chromosomal abnormality. Br J Haematol 1996, 92: 176-83.
39. Quinquandon, I., Claisse, J.F., Capiod, J.C., Delobel, J., Prin, L. α-Interferon and hypereosinophilic syndrome with trisomy 8: Karyotypic remission. Blood 1995, 85: 2284-5.
40. Moraillon, I., Bagot, M., Bournerias, I., Prin, L., Wechsler, J., Revuz, J. Syndrome hyperéosinophilique avec pachydermie précédant un lymphome. Traitement par l'interféron α. Ann Dermatol Venereol 1991, 118: 883-5.
41. Murphy, P.T., Fennelly, D.F., Stuart, M., O'Donnell, J.R. α-Interferon in a case of hypereosinophilic syndrome. Br J Haematol 1990, 75: 619-20.
42. Zielinski, R.M., Lawrence, WD. Interferon-α for the hypereosinophilic syndrome. Ann Intern Med 1990, 113: 716-8.
43. Van den Anker-Lugtenburg, P.J., Van't Veer, M.B. α-Interferon in a case of hypereosinophilic syndrome. Br J Haematol 1990; 76: 258.
44. Busch, F.W., Schmidt, H., Steinke, B. α-Interferon for the hypereosinophilic syndrome. Ann Intern Med 1991, 114: 338-9.
45. Dine, G., Najman, A., Brahimi, S., Culioli, B., Abid, A., Dupoirieux, J. Syndrome hypereosinophilique dans une variété myéloproliférative. Succès après 18 mois d'interféron-α. La Presse Médicale 1992, 21: 1776.
46. Coutant, G., Blétry, O., Prin, L. et al. Traitement des syndromes hyperéosinophiliques à l'expression myéloproliférative par l'association hydroxyurée-interféron α. A propos de sept observations. Ann Méd Intern 1993, 144: 243-50.
47. Butterfield, J.H., Gleich, G.L. Response of six patients with idiopathic hypereosinophilic syndrome to interferon-α. J Allergy Clin Immunol 1994, 94: 1318-26.
48. Bockenstedt, P.L., Santinga, J.T., Boiling, S.F. α-Interferon for idiopathic hypereosinophilic syndrome. Am J Hematol 1994, 45: 248-51.
49. Canonica, G.W., Passalacqua, G., Pronzato, C. et al. Effective long-term α-interferon treatment for hypereosinophilic syndrome. J Allergy Clin Immunol 1995, 96: 131-3.
50. Fruehauf, S., Fiehn, C., Haas, R., Doehner, H., Hunstein, W. Sustained remission of idiopathic hypereosinophilic syndrome following α-interferon therapy. Acta Haematol 1993, 89: 91-3.
51. Demiroglu, H., Dündar, S. Combination of interferon-α and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 1997, 97: 927-9.
52. Desreumaux, P., Janin, A., Dubucquoi, S. et al. Synthesis of interleukin-5 by activated eosinophils in patients with eosinophilic heart disease. Blood 1993, 82: 1553-60.
53. Roth, M.S., Foon, K.A. α-Interferon in the treatment of hematologic malignancies. Am J Med 1986, 81: 871-82.
54. Broxmeyer, H.E., Lu, L., Platzer, E., Feit, C., Juliano, L., Rubin, B.Y. Comparative analysis of the influence of human γ, α and β interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 1983, 131: 1300-5.
55. Aman, M.J., Keller, U., Derigs, G., Mohamadzadeh, M., Huber, C., Peschel, C. Regulation of cytokine expression by interferon-α in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994, 84: 4142-50.
56. Sillaber, C., Geissler, K., Scherrer, R. et al. Type β transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils. Blood 1992, 80: 634-41.
57. Selleri, C., Sato, T., Del Vecchio, L. et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood 1997, 89: 957-64.
58. Egle, A., Villunger, A., Kos, M. et al. Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-α. Eur J Immunol 1996, 26: 3119-26.
59. Jewell, A.P. Interferon-α, Bcl-2 expression and apoptosis in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1996, 21: 43-7.
60. Milner, A.E., Grand, R.J., Waters, C.M., Gregory, C.D. Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene 1993, 8: 3385-91.
61. Panayiotidis, P., Ganeshaguru, K., Foroni, L., Hoffbrand, A.V. Expression and function of the Fas antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995, 9: 1227-32.
62. Parronchi, P., De Carli, M., Manetti, R. et al. IL-4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by TH1 or TH2 human T cell clones. J Immunol 1992, 149: 2977-83.
63. Parronchi, P., Mohapatra, S., Sampognaro, S. et al. Effects of interferon-α on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996, 26: 697-703.
64. Rook, A.M., Gottlieb, S.L., Wolfe, J.T. et al. Pathogenesis of cutaneous T-cell lymphoma: Implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997, 107 (Suppl. 1): 16-20.
65. + T cells. J Clin Invest 1996, 97: 309-15.
66. + T cells and monocytes. Blood 1996, 87: 4731-6.
67. Garcia-Monzon, C., Garcia-Buey, L., Garcia-Sanchez, A., Pajares, J.M., Moreno-Otero, R. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral hepatitis treated with interferon alfa-2b. Gastroenterology 1993, 105: 462-9.
68. + T cell recruitment into tissue. J Immunol 1994, 153: 1264-70.
69. Huang, Y., Blatt, L.M, Taylor, M.W. Type 1 Interferon as an antiinflammatory agent: Inhibition of lipopolysaccharide-induced interleukin-1β and induction of interleukin-1 receptor antagonist. J Interferon Cytokine Res 1995, 15: 317-21.
70. Abu Khabar, K.S., Armstrong, J.A., Ho, M. Type 1 interferons (IFN-α and -β) suppress cytotoxin (tumor necrosis factor-α and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. J Leukoc Biol 1992, 52: 165.
71. Aldebert, D., Lamkhioued, B., Desaint, C. et al. Eosinophils express a functional receptor for interferon-α: Inhibitory role of interferon-α on the release of mediators. Blood 1996, 87: 2354-60.
72. Saito, H., Hayakawa, T., Yui, Y., Shida, T. Effect of human Interferon on different functions of human neutrophils and eosinophils. Int Arch Allergy Appl Immunol 1987, 82: 133-40.
73. Morita, M., Lamkhioued, B., Soussi Gounni, A. et al. Induction by interferons of human eosinophil apoptosis and regulation by interleukin-3, granulocyte/macrophage-colony stimulating factor and interleukin-5. Eur Cytokine Netw 1996, 7: 725-32.
74. Vial, T., Descotes, J. Immune-mediated side effects of cytokines in humans. Toxicology 1995, 105: 31-57.
75. Zabel, P., Schlaak, M. Cyclosporine for hypereosinophilic syndrome. Ann Hematol 1991, 62: 230-1.